ESR1 and breast cancer: EPclin has been shown to predict early and late recurrences in both postmenopausal patients who received ET and pre- and postmenopausal patients who received ET and CTX as adjuvant treatment for ER-positive/HER2-negative primary breast cancer [7–10].